Lv4
544 积分 2025-01-08 加入
Discovery of a Series of Potent, Selective, and Orally Bioavailable Nucleoside Inhibitors of CD73 That Demonstrates In Vivo Antitumor Activity
28天前
已完结
Pancreatic cancer
1个月前
已完结
Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1
1个月前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
1个月前
已完结
Bruton tyrosine kinase inhibitors for multiple sclerosis
2个月前
已完结
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Zanubrutinib in Immune Thrombocytopenia
2个月前
已完结
TLR Engagement Induces an Alternate Pathway for BCR Signaling that Results in PKCδ Phosphorylation
2个月前
已完结
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
